3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
25
Salivary Gland Neoplasms
2
Prostatic Neoplasms, Castration-Resistant
2
Prostatic Diseases
2
Non-metastatic Castration-resistant Prostate Cancer
2
Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Metastatic Castration-resistant Prostate Cancer
2
Male Urogenital Diseases
2
Bulbo-Spinal Atrophy, X-Linked
2
Biochemically Recurrent Prostate Cancer
2
Urogenital Neoplasms
1
Urogenital Diseases
1
Sleep Initiation and Maintenance Disorders
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Neoplasms
1
High-Risk Localized Prostate Cancer
1
Granulosa cell tumor of the ovary
1
Genital Diseases, Male
1
Fatigue
1
Depression
1
Advanced Solid Tumor
1
Adenocarcinoma
1
Interventions
darolutamide
1
Pluvicto
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
High-Risk Localized Prostate Cancer
×
darolutamide
×
90 days
×
Clear all
NCT07450599
2026-05-13
CHINANEO
Bayer
Phase 2
Recruiting
250 enrolled